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ReviewGlossary
Deep sequencing: WGS of a pure sample (e.g., DNA extracted from liquid
culture that was inoculated from a single bacterial colony) is usually sequenced
to at least a 10- to 15-fold depth (i.e., each position in a genome is sequenced
10–15 times). However, when sequencing samples that might be heteroresis-
tant (see below), or might contain multiple strains of the same species, greater
sequencing depth is required to identify minority variants or to separate the
strains [49]. For example, deep sequencing, albeit of sections of the genome
rather than its entirety, is used routinely in clinical applications for genotypic
HIV DST (see below) to detect resistances that occur below 15–20% of the total
population, which is the limit of detection for Sanger sequencing [9].
Drug-susceptibility testing (DST): the process of classifying an isolate or a mix
of isolates from the same species (e.g., in the case of HIV) as susceptible (high
likelihood of clinical response) or resistant (low likelihood of clinical response)
to an antibiotic or antiviral. In some cases, an intermediate category (clinical
success uncertain) is employed [97]. For most pathogens this is achieved using
phenotypic methods, whereas for slow-growing organisms, such as HIV,
genotypic DST is the standard of care [9,98]. WGS will not replace phenotypic
DST for fast-growing organisms given that it would be too expensive, but will
enable rapid genotypic DST for MTBC, for which phenotypic alternatives are
slow [9,49].
DST errors: when comparing two DST methods, a very major error occurs if the
assay under evaluation gives a susceptible result compared with a resistant
result by the reference method. The misclassification of a susceptible reference
result as resistant is referred to as a major error. The classification of a
susceptible or resistant reference result as intermediate, or vice versa, is known
as a minor error [98].
Heteroresistance: a mixture of susceptible and resistant populations, which
may arise as a result of a mixed infection with strains with different
susceptibility patterns, or the evolution of a resistant subpopulation from a
susceptible parental strain during the infection [99]. The ability of different DST
methods to detect resistant isolates at a low percentage of the total population
varies (see deep sequencing) [54].
Metagenomics: unbiased sequencing from a primary sample (i.e., without
isolating or culturing a specific organism). Depending on the type of sample, it
may be highly mixed with several bacterial and viral species as well as host
nucleic acid. Provided that the mixed DNA is sequenced to sufficient depth, the
genome of an organism can be recovered directly from a clinical sample [70].
Whole-genome sequencing (WGS): modern WGS relies on one or a combina-
tion of second- or third-generation sequencing technologies [6]. Although theFollowing recent improvements in sequencing technol-
ogies, whole-genome sequencing (WGS) is positioned
to become an essential tool in the control of antibiotic
resistance, a major threat in modern healthcare. WGS
has already found numerous applications in this area,
ranging from the development of novel antibiotics and
diagnostic tests through to antibiotic stewardship of
currently available drugs via surveillance and the eluci-
dation of the factors that allow the emergence and
persistence of resistance. Numerous proof-of-principle
studies have also highlighted the value of WGS as a tool
for day-to-day infection control and, for some patho-
gens, as a primary diagnostic tool to detect antibiotic
resistance. However, appropriate data analysis plat-
forms will need to be developed before routine WGS
can be introduced on a large scale.
A modern tool for a growing challenge
The spread of antibiotic resistance constitutes one of the
most serious threats to human health [1]. If left unchecked,
even ‘minor surgery and routine operations could become
high risk procedures’ [2]. As a result, the UK Chief Medical
Officer has called for antibiotic resistance to be included in
the National Risk Register [2]. The causes of the spread of
antibiotic resistance are complex, as are the strategies to
combat this threat [3–5]. These include developing novel
agents as well as maximising the utility of currently avail-
able antibiotics by preventing infections and improving
diagnostics. As a result of recent technological advances,
microbial WGS has emerged as a tool that could underpin
the success of such goals.
A detailed discussion of the various sequencing technol-
ogies and their advantages and disadvantages for patho-
gen WGS can be found elsewhere [6–8]. For the purposes of
this review it is merely necessary to appreciate that two
classes of sequencers exist. The first can be compared to oil
tankers in that they are relatively slow but have a high
throughput and low cost (currently approximately $65 per
bacterial genome) [6,9]. By contrast, benchtop sequencers
are akin to speedboats. They have a lower throughput and0168-9525/
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the Illumina MiSeq) but can sequence multiple genomes in
less than 24 h [6,10]. In fact, recent advances in sample
preparation have enabled WGS directly from single bacte-
rial colonies grown under routine diagnostic conditions
without the need for subculture to isolate sufficient DNA
for sequencing [11]. Together, these sequencers have
allowed researchers to interrogate the evolution ofentire genome is sequenced, it cannot be assembled completely if a genome
contains repeated stretches of DNA that are longer than the length of DNA that
can be sequenced in a single read by the sequencing technology employed
[100]. Additional parts of the genome may be excluded for some analyses. For
example, only the core genome that is present in all isolates in question is used
for phylogenetic analyses, which represents about 80% of the entire genome
for Clostridium difficile [62].
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ple, a recent study sequenced the genomes of more than
3000 pneumococcal isolates and another sequenced more
than 3600 group A streptococci [12,13]. In addition, bench-
top sequencers have become sufficiently fast to become
primary diagnostic tools rather than tools for research
or retrospective surveillance [9,14]. We review here the
insights that WGS has provided with regards to antimi-
crobial resistance. Owing to the rapid expansion of this
field, this endeavour must inevitably be a selective one.
WGS to develop novel antibiotics
WGS has become an essential tool for drug development by
enabling the rapid identification of resistance mechanisms,
particularly in the context of tuberculosis (TB), which
remains a global public health emergency [15,16]. In 2005
the first published use of 454 pyrosequencing (the first
second-generation WGS technology) was to identify the
F0 subunit of the ATP synthase as the target of bedaquiline,
which subsequently became the first representative of a
novel class of anti-TB agents to be approved in 40 years
[16,17]. This has enabled researchers to sequence this gene
in phylogenetically diverse reference collections to ensure
that it is conserved across Mycobacterium canettii as well as
the various lineages and species that comprise the Myco-
bacterium tuberculosis complex (MTBC), the causative
agents of TB [18]. This represents an important step because
drug candidates are usually only tested against a small
number of isolates during the early phases of drug develop-
ment. Similarly, only a limited number of MTBC genotypes
are sampled in clinical trials, depending on where these are
conducted [19]. As a result, intrinsically resistant strains
might be missed, as has been the case for PA-824, an anti-TB
agent in Phase III trials [19–21].
The early elucidation of resistance mechanisms using
WGS also has implications for the design of clinical trials.
If resistance mechanisms are discovered that only result
in marginally increased minimal inhibitory concentra-
tions (MICs) compared with the wild type MIC distribu-
tions, more frequent dosing or higher doses could be
employed in clinical trials to overcome this level of resis-
tance. Moreover, the discovery of cross-resistance be-
tween agents using WGS can influence the choice of
antibiotics that are included in novel regimens. TB is
always treated with multiple antibiotics to minimise the
chance of treatment failure as a result of the emergence of
resistance during treatment [22]. Regimens that contain
agents to which a single mutation confers cross-resis-
tance should be avoided if these mutations arise frequent-
ly in vivo. WGS has recently highlighted that this may be
the case with three Phase II trial regimens that contain
bedaquiline and clofazimine because the mutational
upregulation of an efflux pump confers cross-resistance
to both drugs [23].
In addition to being a tool to design clinical trials, WGS
has become an increasingly important tool during clinical
trials. Specifically, it is increasingly being used to distin-
guish exogenous reinfection from relapse of the primary
infection, which is crucial in assessing the efficacy of the
drug or regimens under investigation [24,25]. Traditional
epidemiological tools do not always provide the necessary402resolution for this purpose. This is due to the fact that they
only interrogate minute parts of the genome {e.g., multi-
locus sequence typing (MLST) of Pseudomonas aeruginosa
analyses only 0.18% of the genome [26]}. By contrast, WGS
interrogates the complete (or near-complete) genetic rep-
ertoire of an organism. Therefore, the resolution of WGS is
only limited by the rate of evolution of the pathogen and
will become the gold standard for clinical trials of new anti-
TB agents and other infectious diseases associated with
recurrent disease [27,28].
WGS for surveillance
Surveillance is the cornerstone in the control of infectious
diseases [3,29]. In this context, the ultimate molecular
resolution delivered by WGS has provided unprecedented
insight into the history of the emergence and spread of
antibiotic resistance [30]. In the case of Mycobacterium
abscessus this has resulted in a paradigm shift in the
understanding of its transmission. WGS provided strong
evidence that this non-tuberculous mycobacterium, which
is difficult to treat owing to its intrinsic resistance to many
antibiotics, is transmissible between cystic fibrosis (CF)
patients in the hospital setting [31]. Transmission occurred
despite strict infection control policies that were designed
to prevent the acquisition of other pathogens, such as
epidemic P. aeruginosa (to be discussed below), that are
known to be transmissible between CF patients. Impor-
tantly, this included the transmission of macrolide-resis-
tant isolates whereas environmental M. abscessus isolates
are susceptible to the drug [31]. As a result, the national
infection control guidelines have been revised to minimise
the possibility of further transmission [32]. Moreover, a
much larger UK-wide and international study is currently
underway to investigate the extent of transmission else-
where [33].
WGS has highlighted the importance of the internation-
al spread of antibiotic-resistant organisms [34]. For exam-
ple, the epidemic P. aeruginosa Liverpool strain has been
shown to transmit between CF clinics in the UK and North
America [26]. The development of fluoroquinolone resis-
tance in the EMRSA-15 lineage of methicillin-resistant
Staphylococcus aureus (MRSA) in the mid-1980s preceded
the pandemic spread of this variant [35]. Similarly, the
acquisition of fluoroquinolone resistance has been identi-
fied as a key genetic change linked to the emergence of the
two lineages of epidemic Clostridium difficile (027/BI/
NAP1) during the early 2000s [36].
Large WGS studies have also started to shed light on the
interface between humans and animals. Throughout the
1990s, multidrug-resistant Salmonella Typhimurium
DT104 was responsible for a global epidemic [37]. Contrary
to prior tenets, a comparison of longitudinal human and
livestock isolates from Scotland demonstrated that human
infections were not primarily due to transmission from
local animals. Instead, the human and animal populations
of Typhimurium DT104 in Scotland were largely distinct,
which suggests that other sources of infection, such as
imported food, were responsible for the human disease
[37]. By contrast, WGS demonstrated that livestock-asso-
ciated CC398 MRSA originated from human methicillin-
susceptible S. aureus and acquired methicillin resistance
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humans [38].
WGS to study the emergence of antibiotic resistance
Unlike the aforementioned studies that reconstructed the
evolution of antibiotic resistance using historical isolates,
WGS has also been used to study the evolution of resis-
tance in real-time under a variety of conditions [39]. For
example, Toprak et al. developed a microbial cultivation
system capable of maintaining a constant antibiotic pres-
sure to monitor the evolution of resistance to trimetho-
prim, chloramphenicol, or doxycycline over 20 days in
Escherichia coli [40], whereas Safi et al. relied on antibiot-
ic-containing solid medium to study the evolution of eth-
ambutol resistance in MTBC [41]. The latter study not only
demonstrated that ethambutol resistance emerges in a
stepwise process but also highlighted a novel resistance
mechanism. Specifically, a synonymous mutation in
Rv3792, which would usually be excluded in analyses
aiming to identify the genetic basis of resistance [19],
was found to increase ethambutol MICs by increasing
the expression of the downstream embC gene (probably
by creating an internal promoter) [41]. Subsequently, an
equivalent mechanism was shown to confer isoniazid and
ethionamide cross-resistance in MTBC. In that case, a
synonymous mutation in mabA creates an alternative
promoter for inhA, the shared target of isoniazid and
ethionamide [42].
In addition to elucidating the mechanisms of resistance,
WGS has also played a role in measuring the rate at which
resistance emerges. Ford et al. found that lineage 2 MTBC
isolates (comprising the Beijing genotype, the most fre-
quent MTBC genotype globally) acquire rifampicin resis-
tance at an elevated rate compared with lineage 4 strains
(which are widespread in Africa, the Americas and Europe)
[43–45]. Modelling of these elevated rates suggests that
patients infected with drug-susceptible lineage 2 isolates
have a 22-fold increased risk of having developed multi-
drug resistance (MDR; i.e., resistance to rifampicin and
isoniazid) by the time that they are initially diagnosed,
which highlights the importance of early and active case
detection [45].
WGS has also clarified some of the factors that have
allowed the spread of drug-resistant MTBC. Specifically,
WGS has identified mutations in the a and b’ subunits of
the RNA polymerase that alleviate the fitness costs of
resistance to rifampicin, which constitutes the backbone
of the DOTS (directly observed treatment, short-course)
regimen for drug-susceptible TB [46]. These compensatory
mutations are widespread in MDR MTBC isolates in high-
incidence countries and are associated with ongoing trans-
mission [22,47]. As a result, these isolates are unlikely to
disappear, which underscores the importance of the devel-
opment and deployment of rapid point-of-care drug-sus-
ceptibility testing (DST) assays to identify MDR strains, as
opposed to continuing to rely on empiric treatment, as is
done in most parts of the world [22].
WGS to develop diagnostic tests
The knowledge gained from WGS has been instrumental in
assessing and, if necessary, improving diagnostic assays forDST. For example, the discovery of mecC (a homologue of the
methicillin-resistance gene mecA in S. aureus) using WGS
prompted the redesign of clinical diagnostic PCR assays to
avoid false-negative results [48]. By contrast, it was found
that the phenotypic Vitek 2 DST assay can be adapted to
detecting mecC strains simply by adjusting the default rules
used to interpret the raw data generated by this system [48].
WGS has also started to play an important role in
clarifying the reason for the discrepancies between geno-
typic and phenotypic DST results for MTBC. For most anti-
TB agents the specificity of known resistance mechanisms
is higher than their sensitivity. This means that the cur-
rent generation of genotypic DST assays can usually only
be used to rule-in resistance as opposed to rule-out resis-
tance/confirm susceptibility [9,49]. For some agents, such
as pyrazinamide, false-positive phenotypic DST results are
a known problem, but generally the consensus is that so far
unknown resistance mechanisms are responsible for the
majority of the unexplained phenotypic resistance to many
drugs [22,50]. Indeed, several recent large WGS studies
have identified more than 70 genes that might be involved
in drug resistance [51]. If confirmed, WGS would be the
only option to detect changes in these genes given that the
current generation of rapid genotypic DST assays only
interrogate short stretches of bacterial DNA (discussed
in more detail below) [49]. However, deep WGS studies
have highlighted that the development of resistance is
more dynamic than previously appreciated [52]. In fact,
a recent study found 38% of ofloxacin mono-resistant iso-
lates to be heteroresistant [53]. Importantly, the propor-
tion of ofloxacin resistance that could be explained with
classical gyrA and gyrB mutations increased from 58% to
77% using deep sequencing compared with Sanger se-
quencing [53]. Consequently, the clinical utility of current
molecular assays could be greatly increased if their limit of
detection was improved compared with phenotypic DST –
which is calibrated to detect resistance at 1% or more of the
total population [54]. This also means that novel resistance
mechanisms account for a smaller proportion of phenotypic
resistance than is currently assumed.
In contrast to the above examples of false-negative
results generated by current diagnostic assays, WGS has
also been used to identify false-positive results. For in-
stance, the analysis of WGS data from a large collection of
phylogenetically diverse MTBC isolates demonstrated that
a mutation that is interrogated by a genotypic DST assay
for ethambutol resistance is not a marker for drug resis-
tance [55]. Instead, the mutation represents a marker for
phylogenetically ancestral MTBC, which means that the
DST assay would yield more false-positive than true-posi-
tive results in countries where these ancestral isolates are
dominant [55]. WGS has highlighted similar flaws in the
interpretation of genotypic DST results for streptomycin
and pyrazinamide [56,57]. This underlines that the MTBC
diversity has to be considered when designing and validat-
ing genotypic DST assays [19].
WGS to direct infection control measures in the clinic
The WGS studies discussed so far relied on slow, high-
throughput sequencers to minimise the costs of these large
retrospective projects. However, the introduction of rapid403
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WGS, which could be used to halt the spread of antibiotic-
resistant bacteria. The first organism for which this was
achieved was MRSA [58]. Initially, the investigation by
Harris et al. began as a retrospective study to confirm that
an MRSA outbreak had occurred on a special care baby
unit. Nevertheless, during the data analysis stage of this
project a further infant was found to be potentially colo-
nised with the outbreak strain, despite having been ad-
mitted 64 days after the last MRSA-positive patient had
left the unit, which had also undergone deep cleaning.
Rapid WGS confirmed that the isolate in question was
part of the outbreak, and this led to the hypothesis that a
member of staff might have reintroduced the outbreak
strain after the last gap in the outbreak. Consistent with
this prediction, screening of 154 members of staff identified
one MRSA carrier who, by further rapid WGS, was con-
firmed to be colonised with the outbreak strain. The mem-
ber of staff was relieved of clinical duties and received
decolonisation treatment [58]. No further MRSA isolates
linked to the outbreak were observed on the unit, and this
suggested that the WGS-led intervention brought the out-
break to a halt.
This and other small proof-of-principle studies are
being complemented with much larger hospital-wide lon-
gitudinal and community studies of S. aureus and C.
difficile to study the detailed spread of these pathogens
[10,59–64]. On a very practical level, these studies will
also start to answer the question about how rapid WGS
should be used clinically. Currently, approximately one
third of C. difficile cases in England and only a small
fraction of MRSA carriage and invasive disease are typed
[65]. It remains to be seen whether a blanket policy of WGS
for all cases (as is the case in the UK for MTBC – discussed
below) would be cost-effective, or whether WGS would
be used in an ad hoc manner (e.g., in response to an
increase in cases as in the Harris et al. study [58]). In
effect, it needs to be determined how many cases could be
prevented if WGS data were available in real-time and,
conversely, what the value of disproving an outbreak is,
in which case infection control efforts can be directed
elsewhere [10,66].
WGS to detect antibiotic resistance in the clinic
Several recent studies have compared phenotypic DST
results with the predictions based on WGS data for a variety
of bacterial pathogens [67–69]. Further studies that comprise
thousands of strains are also underway. In one of these
studies, Gordon et al. first compared the routine DST results
for 12 commonly used antibiotics of 501 isolates of S. aureus
with WGS data to develop a panel of resistance determinants
(chromosomal resistance mutations as well as acquired re-
sistance genes) [69]. This panel was subsequently used to
perform WGS DST for a further 491 isolates, which yielded an
overall sensitivity and specificity of 0.97 [95% confidence
interval (95% CI), 0.95–0.98] and 0.99 (95% CI, 0.99–1),
respectively. The overall rate of very major errors and major
errors was 0.5% (95% CI, 0.3–0.7%) and 0.7% (95% CI, 0.5–
0.9%), respectively. Importantly, the error rates were within
the limits set by the FDA for marketing approval (<1.5% very
major discrepancy rate and <3% major discrepancy rate)404for most antibiotics individually, with the exception of
clindamycin and penicillin [69].
Despite the remarkable concordance between genotype
and phenotype observed by Gordon et al., WGS (directly
from primary samples or pure culture) will not become a
primary diagnostic tool to detect antibiotic resistance in
the foreseeable future for S. aureus, nor for the vast
majority of bacterial pathogens for which drug resistance
is considered a major threat [9]. Indeed, unbiased meta-
genomic WGS, albeit technically possible, remains prohib-
itively expensive as a result of contamination with DNA
from other microorganisms and the host [70,71]. Moreover,
WGS is less sensitive than culture or PCR when applied
directly to clinical samples (particularly faecal samples
that are highly mixed) and it can be difficult to assign to
which pathogen a plasmid-borne resistance gene belongs
[70]. Consequently, traditional alternatives such as PCR,
array technologies, and culture will continue to be the
technologies of choice, with the exception of unusual clini-
cal circumstances [72]. Even when starting from a pure
culture, phenotypic DST (e.g., by disc diffusion or automat-
ed liquid-culture methods) remains faster and cheaper
than even the recently developed rapid single-colony
WGS protocol [11]. Nevertheless, the aforementioned data
and algorithms developed by Gordon et al. will be useful for
routine surveillance of novel resistance mechanisms and
quality control (e.g., if an isolate is sequenced for infection
control purposes, the genomic DST result could be routine-
ly compared with the phenotypic results, which will al-
ready be available by the time the WGS result is obtained,
to identify if the right isolate was sequenced or if the
phenotypic DST results were correct).
There are two types of clinical scenarios in which rapid
WGS could play a role in the context of diagnosing antibi-
otic resistance. The first applies when the elucidation of the
resistance mechanism is clinically relevant [11,73]. One
such instance is in linezolid-resistant Enterococcus fae-
cium where distinguishing between mutational and plas-
mid-mediated linezolid resistance can affect the decision to
implement enhanced infection control measures [74]. A
more complex example in this category is that where
carbapenem resistance is detected during screening (e.g.,
using growth in the presence of an indicator carbapenem
[75]). In this context, WGS could be used to distinguish
carbapenemase producers, which demand enhanced infec-
tion control procedures (e.g., enhanced screening or cohort
staffing), from isolates that are carbapenem-resistant by
virtue of other mechanisms [73,75–77]. However, it is
important to appreciate that WGS is unlikely to be cost-
effective compared with currently available alternatives
such as multiplex PCRs or array technology, if used solely
to distinguish resistance mechanisms [4]. By contrast,
WGS will be superior if the data are also used to help
track onward transmission of bacteria or, in the case of a
multi-species carbapenem-resistance outbreak, resistance
plasmid transfer between bacteria [11,73,78,79]. It will
also improve the understanding of the basis of non-con-
gruencies between genotypic and phenotypic data, which
can occur for some carbapenemase-positive organisms that
are phenotypically sensitive but genotypically positive for
a carbapenemase gene [80].
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primary diagnostic tool is when phenotypic testing is
prohibitively slow. For this reason, genotypic DST using
Sanger sequencing of amplicons has been in clinical use for
many years for HIV and is increasingly being replaced with
deep sequencing to allow the detection of low-frequency
mutations (i.e., heteroresistance), to simplify workflows,
and to reduce cost [9]. Current efforts to improve WGS
protocols will allow DST for all currently available anti-
retroviral drugs in a single assay [81]. Phenotypic DST is
also slow and technically demanding for MTBC [9,49].
Molecular techniques have accelerated testing for some
antibiotics (most notably the Xpert MTB/RIF, which si-
multaneously identifies MTBC and rifampicin resistance
in 2 h directly from sputum, and which has become the
front-line diagnostic test in South Africa [16,82]), but the
remaining commercial genotypic DST assays have only
played a limited role because they only target the most
frequent resistance mutations for a limited number of
antibiotics [49]. Owing to the increased resolution that
WGS provides for epidemiological typing for MTBC at a
comparable cost to current methods, rapid WGS will likely
be introduced for every case of TB in England, which is a
low-prevalence area for TB with 5200 culture-confirmed
cases in 2012, to guide contact tracing [83–87]. The same
data could be used for genotypic DST of all known resis-
tance mechanisms simultaneously at no additional cost,
thereby reducing the time required to diagnose highly
drug-resistant cases from weeks to days, depending on
the time to culture positivity [9,49]. In this situation
phenotypic DST would not have to be performed when
well-understood resistance mutations are found. Never-
theless, even with WGS, phenotypic testing will remain
necessary to rule out resistance/confirm susceptibility in
the near future given that deep WGS to detect resistance
mutations at 1% or more of the total population remains
too expensive for routine use, and given that novel resis-
tance mechanisms remain to be discovered, as discussed
above.
Concluding remarks
WGS has become an invaluable tool to combat antibiotic
resistance. Its greatest, yet unfulfilled, potential is as a
primary tool to direct day-to-day infection control in hos-
pitals and the community, as summarised in several recent
reviews [9,14,66,83,88–92]. This is primarily due to the fact
that the current tools available for the automation of WGS
analysis lack many of the features required for clinical use
[9,93–96]. Once this obstacle has been overcome, the full
benefits of WGS as a true platform technology will be
realised by providing superior information compared to
current methods, all while simplifying workflows and pro-
viding unprecedented economies of scale in diagnostic
laboratories [9,11,73].
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